Documente Academic
Documente Profesional
Documente Cultură
Breast Cancer
Indication for metastatic breast cancer (HER2-negative) revoked by FDA in November 2011 due
to failure to delay tumor growth or provide survival benefit
Cervical Cancer
Indicated as part of a combination chemotherapy regimen for persistent, recurrent, or metastatic
carcinoma of the cervix
15 mg/kg IV infusion q3wk
Glioblastoma
Indicated for glioblastoma as a single agent for patients with progressive disease following prior
therapy
10 mg/kg IV q2wk
Exudative ARMD
Off-label indication for exudative age-related macular degeneration
Off-label: 1.25 mg (in 0.05mL of solution) administered by intravitreal injection once monthly
Reference: CATT Research Group, N Engl J Med 2011;364:1897-1908
The need to repackage the drug from the available size vial into a smaller doses increases risk for
transmission of infection if improper aseptic technique occurrs
Adverse Effects
Pharmacology
Mechanism of Action
Recombinant humanized monoclonal antibody to VEGF; blocks the angiogenic molecule VEGF
thereby inhibiting tumor angiogenesis, starving tumor of blood and nutrients
Pharmacokinetics
Metabolism: N/A
Excretion: N/A